Study of the Efficacy and Safety of ICP-332 in Participants With Prurigo Nodularis

NCT07236099 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

135

Enrollment

INDUSTRY

Sponsor class

Conditions

Prurigo Nodularis (PN)

Interventions

DRUG: ICP-322
DRUG: Placebo

Sponsor

Beijing InnoCare Pharma Tech Co., Ltd.